IGC Pharma Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for IGC Pharma stock have an average target of 3.75, with a low estimate of 3.50 and a high estimate of 4.00. The average target predicts an increase of 1,166.89% from the current stock price of 0.30.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.50	$3.75	$4.00	$4.00
Change	+1082.4%	+1166.9%	+1251.4%	+1251.4%

* Price targets were last updated on Dec 5, 2024.

Analyst Ratings

The average analyst rating for IGC Pharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $3.75 → $4	Strong Buy	Maintains	$3.75 → $4	+1,251.35%	Dec 5, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $3.5 → $3.75	Strong Buy	Maintains	$3.5 → $3.75	+1,166.89%	Sep 3, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $3.25 → $3.5	Strong Buy	Maintains	$3.25 → $3.5	+1,082.43%	Jul 29, 2024
James Molloy Alliance Global Partners	Alliance Global Partners	Strong Buy Initiates $3.5	Strong Buy	Initiates	$3.5	+1,082.43%	Jul 17, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Reiterates $3.25	Strong Buy	Reiterates	$3.25	+997.97%	Jun 21, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

1.20M

from 1.35M

-10.56%

from 1.35M

Revenue Next Year

1.36M

from 1.20M

13.38%

from 1.20M

EPS This Year

-0.10

from -0.22

EPS Next Year

-0.10

from -0.10

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	4.07M	898.00K	397.00K	911.00K	1.35M	1.20M	1.36M	1.52M
Revenue Growth	-20.41%	-77.95%	-55.79%	129.47%	47.64%	-10.56%	13.38%	11.07%
EPS	-0.19	-0.21	-0.30	-0.22	-0.22	-0.10	-0.10	-0.09
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.3M	1.5M	1.6M
Avg	1.2M	1.4M	1.5M
Low	1.2M	1.3M	1.5M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-6.3%	22.2%	15.5%
Avg	-10.6%	13.4%	11.1%
Low	-13.8%	6.0%	7.8%

EPS Forecast

EPS	2025	2026	2027
High	-0.09	-0.09	-0.09
Avg	-0.10	-0.10	-0.09
Low	-0.11	-0.12	-0.09

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.